Rocket Pharma doses first patient in Phase 1 study of Danon treatment
Category: #health  By Mateen Dalal  Date: 2019-06-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Rocket Pharma doses first patient in Phase 1 study of Danon treatment

RP-A501 gene therapy can make a significant difference in patients who are suffering from Monogenic Heart Failure Syndrome

Rocket Pharmaceuticals Inc, a multi-platform clinical-stage gene therapy company based in the U.S., recently announced that they have commenced dosing patients in the open-label, Phase 1 clinical study of RP-A501, a gene therapy based on adeno-associated viral vector (AAV) that is developed to treat Danon disease.

Apparently, University of California San Diego (UCSD) Health is the lead and initial center for Phase 1 trial which is led by Barry Greenberg, Director of Advanced Heart Failure Treatment Program at UC San Diego Health and Professor of Medicine at UC San Diego School of Medicine and happens to be the trial’s principal investigator, along with Eric Adler, M.D., Director of Cardiac Transplant and Mechanical Circulatory Support at UCSD Health and Professor of Medicine at UCSD.

Chief Executive Officer and President of Rocket, Gaurav Shah, M.D., said that the Danon disease is a progressive cardiomyopathy wherein the company believes the gene therapy can make a significant difference in patient outcomes. The existing standards of care for Danon are not curative and are generally associated with certain morbidity and mortality.

Consequently, the age of 19 has been reported as the median survival age for male patients suffering for Danon disease, reportedly caused by heart failure, Shah said. This demands an urgent need for alternative options like RP-A501 gene therapy to address patients and families facing the fatal disease.

Dr. Adler said that the development of RP-A501 into clinic is an enormous step towards treating this fatal disease and rare cardiac disorders. UCSD Health is looking forward to being the first and lead center to hold RP-A501 Phase 1 clinical trial and it looks forward to rapidly advance it through the clinic for patients in need.

Apparently, the study is designed to specifically assess the tolerability and safety of RP-A501’s single infusion.

Source Credit- https://rocketpharmaceuticals.gcs-web.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-patient-dosing-has-commenced

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...